围手术期化疗在上、下尿路鳞状细胞癌中的意义
Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
作者信息
Makino Tomoyuki, Izumi Kouji, Natsagdorj Ariunbold, Iwamoto Hiroaki, Kadomoto Suguru, Naito Renato, Kadono Yoshifumi, Mizokami Atsushi
机构信息
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
出版信息
Anticancer Res. 2018 Apr;38(4):2241-2245. doi: 10.21873/anticanres.12467.
BACKGROUND/AIM: To evaluate the clinicopathological characteristics and prognosis of squamous cell carcinoma (SCC) of the urinary tract (UT) urothelium, and investigate the utility of perioperative chemotherapy.
PATIENTS AND METHODS
Thirty-three patients diagnosed with SCC in renal pelvis, ureter and bladder at the Kanazawa University between 2007 and 2017 were included in this retrospective study. Cancer-specific survival (CSS) rates according to cancer stage and neoadjuvant chemotherapy (NAC) were determined.
RESULTS
Among the entire cohort, two-year CSS rates were 100%, 75%, 47% and 0% in stages I, II, III and IV, respectively, with a significant correlation between CSS and cancer stage (p=0.0063). Sixteen patients underwent radical surgery, and seven patients received NAC; however, there were no significant differences in CSS rates among patients stratified by NAC (p=0.7043).
CONCLUSION
Worse cancer stage for SCC of UT urothelium was associated with worse prognosis. Given the poor efficacy of NAC in these patients, surgical treatment should be preferred.
背景/目的：评估尿路（UT）尿路上皮鳞状细胞癌（SCC）的临床病理特征及预后，并探讨围手术期化疗的效用。
患者与方法
本回顾性研究纳入了2007年至2017年间在金泽大学被诊断为肾盂、输尿管及膀胱SCC的33例患者。根据癌症分期及新辅助化疗（NAC）确定癌症特异性生存率（CSS）。
结果
在整个队列中，I、II、III和IV期的两年CSS率分别为100%、75%、47%和0%，CSS与癌症分期之间存在显著相关性（p = 0.0063）。16例患者接受了根治性手术，7例患者接受了NAC；然而，按NAC分层的患者之间CSS率无显著差异（p = 0.7043）。
结论
UT尿路上皮SCC的癌症分期越差，预后越差。鉴于NAC对这些患者疗效不佳，应首选手术治疗。
Zotero 插件